case_images: PMC6480678_01
case_images: PMC6480678_02
case_images: PMC6480678_03
case_images: Clinical courses of case 1 (a) and case 2 (b) during tocilizumab therapy
case_images: 41927_2019_63_Fig1_HTML.jpg
case_images: PMC6480678_05_41927_2019_63_Fig1_HTML.jpg
case_images: Fig1
case_images: DMARD (cyclosporine 150 mg/day) was continued (Fig. 1b). During the 18-month period of TCZ therapy, both RA disease activity and mRSS decreased. At 18 months, the patient global assessment improved by 32 (68 to 36), RA disease activity decreased (DAS28-ESR decreased from 7.14 to 3.70; CDAI decreased from 34.6 to 8.4), and skin thickness evaluated with the mRSS improved from 15 to 7 (Fig. 1b).
case_images: PMC6480678_04
case_images: PMC6480678_05
case_images: Clinical courses of case 1 (a) and case 2 (b) during tocilizumab therapy
case_images: 41927_2019_63_Fig1_HTML.jpg
case_images: PMC6480678_05_41927_2019_63_Fig1_HTML.jpg
case_images: Fig1
case_images: DMARD (cyclosporine 150 mg/day) was continued (Fig. 1b). During the 18-month period of TCZ therapy, both RA disease activity and mRSS decreased. At 18 months, the patient global assessment improved by 32 (68 to 36), RA disease activity decreased (DAS28-ESR decreased from 7.14 to 3.70; CDAI decreased from 34.6 to 8.4), and skin thickness evaluated with the mRSS improved from 15 to 7 (Fig. 1b).
case_images: PMC6480678_06